MEDINCELL S.A. 
New data presented at
According to
Results also showed that to date, there have been no incidents of post-injection delirium/sedation syndrome (PDSS), according to Teva. "This is crucial because the risk of PDSS, along with the associated postinjection monitoring requirement, has been a major barrier to the use of the approved intramuscular olanzapine LAI product," explained
Overall impact of the findings of the long-acting injectables
[Having] no incidents of post-injection delirium/sedation syndrome (PDSS)… is crucial because the risk of PDSS, along with the associated postinjection monitoring requirement, has been a major barrier to the use of the approved intramuscular olanzapine LAI product”
Therefore "we may soon be able to offer schizophrenia treatment for patients taking daily oral olanzapine with a long-acting injectable option that may reduce the risk of this potentially life-threatening side effect," stated Dr
"These new data are quite impactful as improvements in social functioning and quality of life would represent a substantial benefit for people living with schizophrenia and their families. This is an important addition to the positive efficacy results for the primary endpoint of the Phase III study that were announced last May," Malamut added.
Furthermore, Teva shared that real-world analyses found that subcutaneous UZEDY® (risperidone) long acting injectable provided high use and adherence rates in adults with the mental health condition who experience barriers to treatment. A lines of therapy analysis found that UZEDY was employed a first-line option at 12 percent, Teva noted.
Teva is leading clinical development, the regulatory process and commercialisation of UZEDY and TEV-'749.
The post Encouraging data revealed for schizophrenia long-acting injectables appeared first on European Pharmaceutical Review.
© Russell Publishing Limited, 2024. All Rights Reserved., source
